when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
calendar
approval

approval

RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval

December 21, 2021amivantamabupdated 5mo ago

community read0 votes

Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

view source ↗

Data sources

last refreshed 5mo ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

drug timeline · 8

approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalNov 7, 2025 · 327d ago
approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalOct 8, 2025 · 357d ago
approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalSep 3, 2025 · 392d ago
approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 14, 2025 · 412d ago
approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalFeb 14, 2025 · 593d ago
approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalSep 19, 2024 · 741d ago
approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 19, 2024 · 772d ago
approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalMar 1, 2024 · 943d ago

same company · ±60 days · 2

approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 30, 2021
approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJan 21, 2022

🐶 often sniffed alongside

top 5

tagApproval52 co-mentions · 13 sources
drugRYBREVANT48 co-mentions · 13 sources
companyJanssen Biotech Inc26 co-mentions · 13 sources
drugRYBREVANT FASPRO8 co-mentions · 2 sources
drug(amivantamab + hyaluronidase (human recombinant))4 co-mentions · 2 sources

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?